bioRxiv Science⌕ Search

Biology subjects

Payne, O.

Publications and source records attributed to Payne, O..

2 recordsLinked to original sources

Staphylococcus aureus GpsB, Stk, and VraSR form a cell wall surveillance network to maintain cell envelope integrity and mediate antibiotic resistance

Antibiotic resistance is an alarming threat to public health worldwide. Specifically, drug-resistant Staphylococcus aureus remains a major contributor to global mortality. Therefore, in-depth understanding of antibiotic resistance mechanisms is urgently needed to inform alternative therapeutic strategies. We previously showed that GpsB is a critical regulator of cell wall synthesis in S. aureus. GpsB executes its regulatory role via protein-protein interactions. Yet, how GpsB function is modulated in this organism has remained unclear. Intriguingly, a prior proteomics report indicated that GpsB is phosphorylated at six different residues by the sole serine/threonine kinase Stk. Hence, we explored the physiological significance of GpsB phosphorylation. We identify three phosphosites that are each independently sufficient to drive GpsB phosphoregulation, which likely alters its partner preference. We find that cells lacking gpsB exhibit heightened fosfomycin sensitivity, and that this is exacerbated by stk deletion. Our findings reveal that GpsB collaborates with Stk and the VraSR cell wall stress response system to coordinate the demand-driven availability of cell wall precursors. Collectively, this report establishes GpsB as a pivotal peptidoglycan supply chain sentinel that together with Stk and VraSR forms an integrated cell wall stress monitoring network that maintains cell envelope homeostasis and aids in antibiotic resistance.

microbiology↗

Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFN non-response

Background and aimsType one (T1) and three interferons (T3IFNs) are implicated in Chronic Hepatitis B (CHB) immunopathogenesis. IFN remains the only licenced immune modulating therapy for CHB. We measured the prevalence of auto-antibodies (auto-Abs) against T1 and T3IFNs to examine the hypothesis that they impact Hepatitis B Virus (HBV) control and treatment response, as highlighted by COVID-19. MethodsOur multi-centre retrospective longitudinal study accessed two CHB cohorts, auto-Ab levels and neutralisation status were measured against T1IFN and T3IFN. Associations were tested against HBV clinical parameters. ResultsOverall, 11.9% (33/276) of CHB patients had any detectable anti-IFN auto-Abs and 9.8% (27/276) anti-T3IFN auto-Abs, with high incidence of PegIFN-induced de novo auto-Ab (25.7%, 9/35). However, only a minority of auto-Ab-positive sera demonstrated neutralisation in vitro (3/33, 9.1%). Auto-Ab-positivity correlated with higher median HBsAg levels (p=0.0024). All individuals with detectable auto-Ab were PegIFN non-responders including those without auto-Ab against IFN specifically. ConclusionsNon-neutralising anti-IFN auto-Abs are common in CHB and associate with higher median HBsAg levels. Further prospective study of anti-cytokine auto-Ab in CHB are required to characterise association with long-term outcomes. Impact and implicationsHBV and PegIFN individually may induce broad auto-reactivity associated with dysregulated anti-viral immune responses. Auto-Ab screening pre-PegIFN and other immunotherapies may have a critical role in stratifying patient selection.

immunology↗